These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36182105)

  • 21. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings.
    Dunavin N; Mau LW; Meyer CL; Divine C; Abdallah AO; Leppke S; D'Souza A; Denzen E; Saber W; Burns LJ; Ganguly S
    Biol Blood Marrow Transplant; 2020 Apr; 26(4):805-813. PubMed ID: 31917269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acupuncture for reduction of symptom burden in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation: a randomized sham-controlled trial.
    Deng G; Giralt S; Chung DJ; Landau H; Siman J; Search B; Coleton M; Vertosick E; Shapiro N; Chien C; Wang XS; Cassileth B; Mao JJ
    Support Care Cancer; 2018 Feb; 26(2):657-665. PubMed ID: 28920142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
    Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modified high-dose melphalan and autologous SCT for AL amyloidosis or high-risk myeloma: analysis of SWOG trial S0115.
    Sanchorawala V; Hoering A; Seldin DC; Finn KT; Fennessey SA; Sexton R; Mattar B; Safah HF; Holmberg LA; Dean RM; Orlowski RZ; Barlogie B
    Bone Marrow Transplant; 2013 Nov; 48(12):1537-42. PubMed ID: 23852321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis.
    Shah N; Shi Q; Williams LA; Mendoza TR; Wang XS; Reuben JM; Dougherty PM; Bashir Q; Qazilbash MH; Champlin RE; Cleeland CS; Giralt SA
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):226-231. PubMed ID: 26253006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
    El-Jawahri A; LeBlanc T; VanDusen H; Traeger L; Greer JA; Pirl WF; Jackson VA; Telles J; Rhodes A; Spitzer TR; McAfee S; Chen YA; Lee SS; Temel JS
    JAMA; 2016 Nov; 316(20):2094-2103. PubMed ID: 27893130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomised, phase 3 trial.
    Bashir Q; Thall PF; Milton DR; Fox PS; Kawedia JD; Kebriaei P; Shah N; Patel K; Andersson BS; Nieto YL; Valdez BC; Parmar S; Rondon G; Delgado R; Hosing C; Popat UR; Oran B; Ciurea SO; Lin P; Weber DM; Thomas SK; Lee HC; Manasanch EE; Orlowski RZ; Williams LA; Champlin RE; Qazilbash MH
    Lancet Haematol; 2019 May; 6(5):e266-e275. PubMed ID: 30910541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation.
    Abdelhakim H; Shune L; Bhatti S; Cantilena AR; Baran A; Lin TL; Ganguly S; Singh AK; Abhyankar S; Divine C; Lipe B; McGuirk J; Allin D; Aljitawi OS
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1713-1719. PubMed ID: 31170519
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety of outpatient autologous hematopoietic cell transplantation for multiple myeloma and lymphoma.
    Graff TM; Singavi AK; Schmidt W; Eastwood D; Drobyski WR; Horowitz M; Palmer J; Pasquini M; Rizzo DJ; Saber W; Hari P; Fenske TS
    Bone Marrow Transplant; 2015 Jul; 50(7):947-53. PubMed ID: 25867651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib-cyclophosphamide-dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial.
    Yong K; Wilson W; de Tute RM; Camilleri M; Ramasamy K; Streetly M; Sive J; Bygrave CA; Benjamin R; Chapman M; Chavda SJ; Phillips EH; Del Mar Cuadrado M; Pang G; Jenner R; Dadaga T; Kamora S; Cavenagh J; Clifton-Hadley L; Owen RG; Popat R
    Lancet Haematol; 2023 Feb; 10(2):e93-e106. PubMed ID: 36529145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcomes of innovator versus generic melphalan formulation in autologous hematopoietic cell transplantation for multiple myeloma.
    Lad DP; Malhotra P; Patil AN; Nampoothiri RV; Kasudhan KS; Khadwal A; Prakash G; Jain A; Malhotra S; Varma N; Attri SV; Varma S
    Hematol Oncol Stem Cell Ther; 2021 Jun; 14(2):114-118. PubMed ID: 32622756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis.
    Badar T; Khan MA; Szabo A; Drobyski W; Chhabra S; Dhakal B; Fenske TS; Hamadani M; Hari P; Jerkins JH; Shah NN; Shaw BE; D'Souza A
    Amyloid; 2019 Dec; 26(4):210-215. PubMed ID: 31347424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma.
    Shah N; Cornelison AM; Saliba R; Ahmed S; Nieto YL; Bashir Q; Parmar S; Hosing C; Popat U; Shpall EJ; Champlin RE; Qazilbash M
    Eur J Haematol; 2017 Dec; 99(6):532-535. PubMed ID: 28895206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
    Bashir Q; Shah N; Parmar S; Wei W; Rondon G; Weber DM; Wang M; Orlowski RZ; Thomas SK; Shah J; Qureshi SR; Dinh YT; Popat U; Anderlini P; Hosing C; Giralt S; Champlin RE; Qazilbash MH
    Leuk Lymphoma; 2012 Jan; 53(1):118-22. PubMed ID: 21780997
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploring the caregiver's experience in an innovative homebound hematopoietic stem cell transplantation program.
    Jenkelowitz J; Garzon MG; Lynch K; Shuk E; Feindler E; Landau H; Applebaum A
    Palliat Support Care; 2021 Aug; 19(4):397-404. PubMed ID: 33118909
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-Dose Bendamustine, Etoposide, Cytarabine, and Melphalan (BeEAM) Conditioning Before Autologous Transplantation for Patients With Multiple Myeloma.
    Solomon SR; Brown S; Shegda N; Jackson KC; Zhang X; Bashey A; Holland HK; Morris LE; Solh M
    Transplant Cell Ther; 2022 Aug; 28(8):486.e1-486.e7. PubMed ID: 35598842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcome of Patients with Immunoglobulin Light-Chain Amyloidosis with Lung, Liver, Gastrointestinal, Neurologic, and Soft Tissue Involvement after Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Saliba RM; Hamdi A; El Fakih R; Varma A; Dinh YT; Rondon G; Cornelison AM; Shah ND; Bashir Q; Shah JJ; Hosing C; Popat U; Orlowski RZ; Champlin RE; Parmar S; Qazilbash MH
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1413-7. PubMed ID: 25842049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical care for patients receiving autologous hematopoietic stem cell transplantation in the home setting.
    Herrmann RP; Leather M; Leather HL; Leen K
    Oncol Nurs Forum; 1998 Sep; 25(8):1427-32. PubMed ID: 9766296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.